Compositions and methods employing alternative reading frame polypeptides for the treatment of cancer and infectious disease
CA 2514288 C · Owner: Dendreon Corporation · Inventors: Graddis, Thomas; Diegel, Michael; Vidovic, Damir
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Provided are alternative reading frame (ARF) polypeptides as well as antigen presenting cell (APC) and dendritic cell (DC) based compositions and methods that employ alternative reading frame polypeptides. ARF polypeptides and ARF polypeptide-based compositions and methods are useful in the treatment of cancer and infectious disease.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed March 5, 2004 and granted July 7, 2015. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended March 5, 2024.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by March 5, 2026.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.